CicloMed announces first patient in phase I trial of patients with advanced tumors
The CPX-POM-001 study is examining the safety, dose tolerance, pharmacokinetics and pharmacodynamics of Ciclopirox Prodrug on patients with bladder cancer. Read More
Scott Weir named Research Recipient of the 2018 Global Health Repurposing Awards
Cures Within Reach announced that Scott Weir, Pharm.D., Ph.D., is the recipient of the 2018 Janet Davison Rowley Patient Impact Research Award. Learn More
KU Cancer Center and Children's Mercy receive grant for childhood cancer research
Braden's Hope announced it will award $3 million to advance childhood cancer research at The University of Kansas Cancer Center and Children's Mercy. Learn more
Institute for Advancing Medical Innovation
The Institute for Advancing Medical Innovation (IAMI) serves as a national model for philanthropy, industry and universities to collaborate in advancing university innovations in life sciences by:
Vision Change the standard of care for pediatric, adolescent and adult patients living with diseases including cancer and rare diseases.
Mission Discover and develop pharmaceuticals and diagnostics with a clear path to market.
Core Hypothesis The investment in high potential academic projects with industry-experienced leadership will enhance the yield of commercial products that benefit patients.
Children's Mercy Kansas City
Together, IAMI and Children's Mercy Kansas City have advanced several discoveries to patient treatments.
Frontiers: University of Kansas Clinical and Translational Science Institute
IAMI and Frontiers accelerate the process of lab discoveries becoming patient treatments.
KU Cancer Center
Innovation and discovery drive the partnership between The University of Kansas Cancer Center and IAMI.
KU Endowment financially supports IAMI to bring new drugs and treatments to the market.
Jan 08, 2018